Guggenheim Maintains Buy on Eloxx Pharma, Lowers Price Target to $40

Benzinga · 3d ago
Guggenheim analyst Vamil Divan maintains Eloxx Pharma (NASDAQ:ELOX) with a Buy and lowers the price target from $43 to $40.